(VIANEWS) – The NASDAQ ended the session with FibroGen jumping 12.85% to $1.10 on Thursday, after three sequential sessions in a row of gains. NASDAQ jumped 0.18% to $15,510.50, after five consecutive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
FibroGen’s last close was $0.97, 96.22% under its 52-week high of $25.69.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be oversold (<=20).
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is 1.67.
Sales Growth
FibroGen’s sales growth is 5.3% for the ongoing quarter and 16.4% for the next.
Volume
Today’s last reported volume for FibroGen is 1821140 which is 3.5% above its average volume of 1759550.
More news about FibroGen (FGEN).
